Company intelligence / Profile preview

F2G Consultoria

Ownership: Private
Development stage: Other

Overview

F2G is developing a novel class of antifungal agents called orotomides. Their lead candidate, olorofim, has shown effectiveness against a broad range of rare and resistant mould infections and has received orphan drug status from both the FDA and EMA. Clinical data indicate activity where existing treatments fail[4].

Therapeutic areas: Infectious Diseases
Modalities: Small molecule
Industry: Biotech

Partnerships

Shionogi Co., Ltd. (collaboration for development/commercialization in Asia)

Beyond the preview

Go deeper on F2G Consultoria.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on F2G Consultoria.

Explore the full profile